fosbretabulin tromethamine

DRUG3 trials

Sponsors

National Cancer Institute (NCI), Mateon Therapeutics

Conditions

Neuroendocrine TumorsPlatinum Resistant Ovarian CancerRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Phase 2

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

CompletedNCT01305213

National Cancer Institute (NCI)Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

Start: 2011-03-21End: 2016-11-03Updated: 2019-07-30

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

CompletedNCT02132468

Mateon TherapeuticsNeuroendocrine Tumors

Start: 2014-09-30End: 2016-08-31Updated: 2017-12-05

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

TerminatedNCT02641639

Mateon TherapeuticsPlatinum Resistant Ovarian Cancer

Start: 2016-06-30End: 2017-10-31Updated: 2025-03-24

Related Papers

The development and use of vascular targeted therapy in ovarian cancer.

2017-02-2465 citations

A phase II study of combretastatin A4-phosphate (CA4P) in the treatment of well-differentiated, low- to intermediate-grade, unresectable, recurrent, or metastatic pancreatic, or GI neuroendocrine tumors/carcinoid (GI-NETs/PNETs) with elevated biomarkers.

Journal of Clinical Oncology2017-02-015 citations